Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
about
Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanomaA quest for therapeutic antigens in bone and soft tissue sarcomaA combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses.Immune checkpoint inhibitor therapy associated hypophysitisRegulatory T cell: a protection for tumour cellsReview of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experienceCD28 co-stimulation in T-cell homeostasis: a recent perspectiveCo-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamilyBiologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanomaThe price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkImmune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challengeModulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanomaInterface of signal transduction inhibition and immunotherapy in melanoma.CTLA4 blockade broadens the peripheral T-cell receptor repertoireCytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapyImmune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cellsHave we overestimated the benefit of human(ized) antibodies?Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trialA multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.Releasing the brake on the immune system: ipilimumab in melanoma and other tumorsImmunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malariaEnterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfaCTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis.Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2',3'-dideoxyinosine and stavudine following cytotoxic-T-lymphocyte-associated antigen 4 and indoleamine 2,3-dioxygenase blockadeInfluence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells.Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare diseaseCTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion.Inhibitory costimulation and anti-tumor immunity.Ipilimumab pharmacotherapy in patients with metastatic melanoma.
P2860
Q24618690-9A53E216-DADA-40E2-9DD9-FAEC109108BFQ24814654-58B2E93C-10B2-439D-9737-36E7A4F5246EQ24816925-FA02D7B4-A3A0-4927-AA4C-DD46D4AF6FD1Q26827140-56A54D55-825E-4D37-B37A-308D281F45C1Q26991447-0ADF48E9-D2F7-4E88-9307-CCD74ACE3D89Q26995499-41F4D9DA-61F1-4DBD-8B58-8252B1A82C5DQ27007031-B7EC6C65-A6E4-47D9-A5F9-97F05190F7EAQ28271806-12D8F7E2-BB2C-48A5-96DE-7B2B62D8C709Q28307216-BCFE3C83-B143-45B3-80A4-458F1CF6A367Q28485085-F9E5006D-F08D-4EA3-B01B-5E91CF89315CQ28740359-0E832B57-6B72-4F1F-A968-97923BDC7380Q28749278-696B658F-D02C-47A3-814D-DA45FB56001FQ30429380-D7676A2D-01FA-4EC6-8220-5A1303110A4AQ33560753-E772EA99-D946-4156-A39D-9C10E395FA09Q33710973-99E2D505-1999-4279-A2D6-1AB278320598Q33841397-A4133E77-28F6-446F-AC6B-E0D9377EEEA0Q33992829-ABF71BBE-21B0-4C84-8092-E82DD6D5A39DQ33995866-6BB57FB2-7EE0-4AAA-8255-DC69E26FE8A5Q34142714-BD314C97-FAC5-4C9A-89B3-0AB817A9BF5FQ34335379-914198DF-B5AF-431F-814A-51AFA01D0AE0Q34387506-11C5C7DF-F7E2-4663-B9EF-C30BF09BB5F0Q34447732-70920100-941E-4310-BB08-882BBABFEE3CQ34492813-6F8933BE-EFE1-40E3-B5FC-EF091CB784B6Q34567635-D4007ACF-9D08-4516-900B-366867389648Q34591128-C4EFB656-336A-4936-9BB8-3D0867F9E8DBQ34633278-21D14F20-2933-46D2-AAAD-F91D012E6FD3Q34657638-F57B13A1-7881-4F00-9904-411F0EE957A0Q35009889-CE820902-7F4C-4344-B34A-A84CF500C142Q35020518-0D77C622-D500-4CC3-A67C-BF05C4309F16Q35053486-1D006E21-6408-4316-A1BC-E2BA4863E963Q35150452-9C6183AB-2BC9-4F7B-8742-19AD5F15C5A6Q35666030-48CCF74A-1BF3-4B6B-BCFC-CE3EE097260FQ35747554-2F41E5C0-B4C9-4E6A-A760-3EAB7E31207BQ35815759-F23D76B8-AEC6-4620-B7BD-47FD586FC2A7Q35832390-EFD9C636-FF2F-481A-8417-295A1C16BF8AQ35848881-0DED2F45-940F-4BD4-B64B-5A0653B8B28DQ35913194-9FFF81E8-DF22-4C96-9825-98F8B412C45DQ35945339-9396F143-9341-463B-8772-0345ED4ACCD5Q36016292-9A0D4F24-04C4-49CE-B205-50A30FC7CDECQ36161313-2409EE0D-083A-4DBB-94E8-71B8867E6DED
P2860
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Autoimmunity in a phase I tria ...... ed stages III and IV melanoma.
@en
Autoimmunity in a phase I tria ...... ed stages III and IV melanoma.
@nl
type
label
Autoimmunity in a phase I tria ...... ed stages III and IV melanoma.
@en
Autoimmunity in a phase I tria ...... ed stages III and IV melanoma.
@nl
prefLabel
Autoimmunity in a phase I tria ...... ed stages III and IV melanoma.
@en
Autoimmunity in a phase I tria ...... ed stages III and IV melanoma.
@nl
P2093
P921
P356
P1476
Autoimmunity in a phase I tria ...... ed stages III and IV melanoma.
@en
P2093
Dongxin Liu
Geoffrey Nichol
Jeffrey Weber
Jolie Snively
Kristin Sanderson
Michael Yellin
Ronald Scotland
Shirley Sian
Susan Groshen
P304
P356
10.1200/JCO.2005.01.128
P407
P577
2004-12-21T00:00:00Z